Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150916 | 1.00 | DDB1 (0.42) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL71530 | 0.83 | DDB1 (0.46) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL8907523 | 0.83 | DDB1 (0.46) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10785422 | 0.82 | DDB1 (0.42) | DDB1CRBNALDH1A1 | |
| SCHEMBL11435272 | 0.81 | DDB1 (0.41) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10572588 | 0.81 | DDB1 (0.41) | DDB1CRBNALDH1A1 | |
| SCHEMBL7378927 | 0.81 | DDB1 (0.41) | DDB1CRBNALDH1A1 | |
| SCHEMBL1150970 | 0.80 | DDB1 (0.41) | DDB1CRBNALDH1A1 | |
| SCHEMBL9076521 | 0.79 | DDB1 (0.40) | DDB1CRBNALDH1A1 | |
| SCHEMBL11651013 | 0.78 | SLC6A2 (0.44) | DDB1CRBNALDH1A1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| CN-102219750-B | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ANGELETTI P IST RICHERCHE BIO | 2013-05-29 | — | — | CN | disclosed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| CN-1700918-B | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ANGELETTI P IST RICHERCHE BIO | 2011-06-08 | — | — | CN | disclosed |
| US-7528124-B2 | 1,3-dihydro-2H-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1659121-A1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| CN-1700918-A | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ANGELETTI P IST RICHERCHE BIO (IT) | 2005-11-23 | — | — | CN | disclosed |
| EP-1465891-A4 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARM INC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1465891-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1441735-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003057144-A2 | CHANGE INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003057666-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003035077-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | DDB1 1156/4885CRBN 395/4885ALDH1A1 1619/4885 |
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | AVPR1B, AVPR2, AVPR1A | DDB1 1308/4885CRBN 4159/4885ALDH1A1 1072/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | DDB1 1156/4885CRBN 395/4885ALDH1A1 1619/4885 |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | DDB1 910/4885CRBN 3027/4885ALDH1A1 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.